nodes	percent_of_prediction	percent_of_DWPC	metapath
Cyclophosphamide—CYP3A7—Vincristine—muscle cancer	0.0721	0.124	CbGbCtD
Cyclophosphamide—CYP3A7-CYP3A51P—Vincristine—muscle cancer	0.0721	0.124	CbGbCtD
Cyclophosphamide—ABCB1—Dactinomycin—muscle cancer	0.0571	0.0984	CbGbCtD
Cyclophosphamide—CYP3A5—Vincristine—muscle cancer	0.0541	0.0931	CbGbCtD
Cyclophosphamide—CYP3A5—Etoposide—muscle cancer	0.0495	0.0853	CbGbCtD
Cyclophosphamide—CYP2C8—Etoposide—muscle cancer	0.0476	0.0821	CbGbCtD
Cyclophosphamide—CYP2B6—Doxorubicin—muscle cancer	0.0429	0.0739	CbGbCtD
Cyclophosphamide—ABCB1—Vincristine—muscle cancer	0.0352	0.0606	CbGbCtD
Cyclophosphamide—ABCB1—Etoposide—muscle cancer	0.0322	0.0555	CbGbCtD
Cyclophosphamide—ABCB1—Doxorubicin—muscle cancer	0.022	0.0379	CbGbCtD
Cyclophosphamide—ABCB1—Methotrexate—muscle cancer	0.0213	0.0367	CbGbCtD
Cyclophosphamide—CYP3A4—Vincristine—muscle cancer	0.0211	0.0363	CbGbCtD
Cyclophosphamide—CYP2D6—Doxorubicin—muscle cancer	0.0207	0.0357	CbGbCtD
Cyclophosphamide—CYP3A4—Etoposide—muscle cancer	0.0193	0.0333	CbGbCtD
Cyclophosphamide—CYP3A4—Doxorubicin—muscle cancer	0.0132	0.0227	CbGbCtD
Cyclophosphamide—Discomfort—Dactinomycin—muscle cancer	0.000378	0.000902	CcSEcCtD
Cyclophosphamide—Cystitis noninfective—Doxorubicin—muscle cancer	0.000377	0.000899	CcSEcCtD
Cyclophosphamide—Influenza like illness—Doxorubicin—muscle cancer	0.000375	0.000894	CcSEcCtD
Cyclophosphamide—Cystitis—Doxorubicin—muscle cancer	0.000373	0.000889	CcSEcCtD
Cyclophosphamide—Diabetes mellitus—Methotrexate—muscle cancer	0.000372	0.000887	CcSEcCtD
Cyclophosphamide—Hypoaesthesia—Etoposide—muscle cancer	0.000372	0.000887	CcSEcCtD
Cyclophosphamide—Anaemia—Vincristine—muscle cancer	0.000371	0.000885	CcSEcCtD
Cyclophosphamide—Colitis—Doxorubicin—muscle cancer	0.000371	0.000884	CcSEcCtD
Cyclophosphamide—Agitation—Vincristine—muscle cancer	0.000369	0.00088	CcSEcCtD
Cyclophosphamide—Polyuria—Methotrexate—muscle cancer	0.000369	0.000879	CcSEcCtD
Cyclophosphamide—Oedema—Dactinomycin—muscle cancer	0.000367	0.000875	CcSEcCtD
Cyclophosphamide—Fluid retention—Doxorubicin—muscle cancer	0.000367	0.000874	CcSEcCtD
Cyclophosphamide—Infection—Dactinomycin—muscle cancer	0.000365	0.000869	CcSEcCtD
Cyclophosphamide—Hepatic failure—Methotrexate—muscle cancer	0.00036	0.000859	CcSEcCtD
Cyclophosphamide—Leukopenia—Vincristine—muscle cancer	0.00036	0.000857	CcSEcCtD
Cyclophosphamide—Thrombocytopenia—Dactinomycin—muscle cancer	0.000359	0.000857	CcSEcCtD
Cyclophosphamide—Erythema multiforme—Etoposide—muscle cancer	0.000353	0.000843	CcSEcCtD
Cyclophosphamide—Renal failure acute—Methotrexate—muscle cancer	0.000351	0.000836	CcSEcCtD
Cyclophosphamide—Anorexia—Dactinomycin—muscle cancer	0.00035	0.000834	CcSEcCtD
Cyclophosphamide—Neoplasm—Doxorubicin—muscle cancer	0.000349	0.000832	CcSEcCtD
Cyclophosphamide—Bladder pain—Doxorubicin—muscle cancer	0.000349	0.000832	CcSEcCtD
Cyclophosphamide—Mouth ulceration—Doxorubicin—muscle cancer	0.000349	0.000832	CcSEcCtD
Cyclophosphamide—Convulsion—Vincristine—muscle cancer	0.000348	0.00083	CcSEcCtD
Cyclophosphamide—Flushing—Etoposide—muscle cancer	0.000347	0.000827	CcSEcCtD
Cyclophosphamide—Hypertension—Vincristine—muscle cancer	0.000347	0.000827	CcSEcCtD
Cyclophosphamide—Pulmonary oedema—Doxorubicin—muscle cancer	0.000344	0.000819	CcSEcCtD
Cyclophosphamide—Myalgia—Vincristine—muscle cancer	0.000342	0.000815	CcSEcCtD
Cyclophosphamide—Chills—Etoposide—muscle cancer	0.000335	0.0008	CcSEcCtD
Cyclophosphamide—Sepsis—Doxorubicin—muscle cancer	0.000335	0.000799	CcSEcCtD
Cyclophosphamide—Musculoskeletal discomfort—Dactinomycin—muscle cancer	0.000334	0.000797	CcSEcCtD
Cyclophosphamide—Alopecia—Etoposide—muscle cancer	0.00033	0.000787	CcSEcCtD
Cyclophosphamide—Anaphylactic shock—Vincristine—muscle cancer	0.000328	0.000782	CcSEcCtD
Cyclophosphamide—Oedema—Vincristine—muscle cancer	0.000328	0.000782	CcSEcCtD
Cyclophosphamide—Infection—Vincristine—muscle cancer	0.000326	0.000776	CcSEcCtD
Cyclophosphamide—Phlebitis—Doxorubicin—muscle cancer	0.000325	0.000776	CcSEcCtD
Cyclophosphamide—Diabetes mellitus—Doxorubicin—muscle cancer	0.000322	0.000768	CcSEcCtD
Cyclophosphamide—Thrombocytopenia—Vincristine—muscle cancer	0.000321	0.000765	CcSEcCtD
Cyclophosphamide—Hepatic function abnormal—Doxorubicin—muscle cancer	0.000321	0.000765	CcSEcCtD
Cyclophosphamide—Decreased appetite—Dactinomycin—muscle cancer	0.000319	0.00076	CcSEcCtD
Cyclophosphamide—Dysgeusia—Etoposide—muscle cancer	0.000319	0.00076	CcSEcCtD
Cyclophosphamide—Hyperhidrosis—Vincristine—muscle cancer	0.000317	0.000756	CcSEcCtD
Cyclophosphamide—Fatigue—Dactinomycin—muscle cancer	0.000316	0.000754	CcSEcCtD
Cyclophosphamide—Pain—Dactinomycin—muscle cancer	0.000314	0.000748	CcSEcCtD
Cyclophosphamide—Muscle spasms—Etoposide—muscle cancer	0.000313	0.000746	CcSEcCtD
Cyclophosphamide—Anorexia—Vincristine—muscle cancer	0.000313	0.000745	CcSEcCtD
Cyclophosphamide—Hepatic failure—Doxorubicin—muscle cancer	0.000312	0.000743	CcSEcCtD
Cyclophosphamide—Cardiac failure congestive—Doxorubicin—muscle cancer	0.000309	0.000737	CcSEcCtD
Cyclophosphamide—Hypotension—Vincristine—muscle cancer	0.000306	0.00073	CcSEcCtD
Cyclophosphamide—Renal failure acute—Doxorubicin—muscle cancer	0.000304	0.000724	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Dactinomycin—muscle cancer	0.000302	0.000721	CcSEcCtD
Cyclophosphamide—Ill-defined disorder—Etoposide—muscle cancer	0.000302	0.00072	CcSEcCtD
Cyclophosphamide—Anaemia—Etoposide—muscle cancer	0.000301	0.000717	CcSEcCtD
Cyclophosphamide—Hot flush—Doxorubicin—muscle cancer	0.0003	0.000714	CcSEcCtD
Cyclophosphamide—Musculoskeletal discomfort—Vincristine—muscle cancer	0.000299	0.000712	CcSEcCtD
Cyclophosphamide—Menopausal symptoms—Doxorubicin—muscle cancer	0.000297	0.000708	CcSEcCtD
Cyclophosphamide—Renal impairment—Doxorubicin—muscle cancer	0.000295	0.000702	CcSEcCtD
Cyclophosphamide—Paraesthesia—Vincristine—muscle cancer	0.000294	0.000702	CcSEcCtD
Cyclophosphamide—Malaise—Etoposide—muscle cancer	0.000293	0.0007	CcSEcCtD
Cyclophosphamide—Dermatitis bullous—Doxorubicin—muscle cancer	0.000293	0.000699	CcSEcCtD
Cyclophosphamide—Toxic epidermal necrolysis—Methotrexate—muscle cancer	0.000291	0.000695	CcSEcCtD
Cyclophosphamide—Leukopenia—Etoposide—muscle cancer	0.000291	0.000694	CcSEcCtD
Cyclophosphamide—Body temperature increased—Dactinomycin—muscle cancer	0.00029	0.000692	CcSEcCtD
Cyclophosphamide—Cardiac failure—Doxorubicin—muscle cancer	0.000287	0.000685	CcSEcCtD
Cyclophosphamide—Decreased appetite—Vincristine—muscle cancer	0.000285	0.000679	CcSEcCtD
Cyclophosphamide—Cough—Etoposide—muscle cancer	0.000284	0.000677	CcSEcCtD
Cyclophosphamide—Fatigue—Vincristine—muscle cancer	0.000283	0.000674	CcSEcCtD
Cyclophosphamide—Convulsion—Etoposide—muscle cancer	0.000282	0.000672	CcSEcCtD
Cyclophosphamide—Hyponatraemia—Doxorubicin—muscle cancer	0.000281	0.000671	CcSEcCtD
Cyclophosphamide—Hypertension—Etoposide—muscle cancer	0.000281	0.00067	CcSEcCtD
Cyclophosphamide—Constipation—Vincristine—muscle cancer	0.00028	0.000668	CcSEcCtD
Cyclophosphamide—Pain—Vincristine—muscle cancer	0.00028	0.000668	CcSEcCtD
Cyclophosphamide—Gastrointestinal haemorrhage—Doxorubicin—muscle cancer	0.00028	0.000668	CcSEcCtD
Cyclophosphamide—Chest pain—Etoposide—muscle cancer	0.000277	0.00066	CcSEcCtD
Cyclophosphamide—Discomfort—Etoposide—muscle cancer	0.000274	0.000653	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Dactinomycin—muscle cancer	0.00027	0.000645	CcSEcCtD
Cyclophosphamide—Abdominal discomfort—Methotrexate—muscle cancer	0.000268	0.000639	CcSEcCtD
Cyclophosphamide—Confusional state—Etoposide—muscle cancer	0.000268	0.000638	CcSEcCtD
Cyclophosphamide—Cardiac arrest—Doxorubicin—muscle cancer	0.000267	0.000635	CcSEcCtD
Cyclophosphamide—Pancytopenia—Methotrexate—muscle cancer	0.000266	0.000633	CcSEcCtD
Cyclophosphamide—Anaphylactic shock—Etoposide—muscle cancer	0.000266	0.000633	CcSEcCtD
Cyclophosphamide—Infection—Etoposide—muscle cancer	0.000264	0.000629	CcSEcCtD
Cyclophosphamide—Asthenia—Dactinomycin—muscle cancer	0.000263	0.000628	CcSEcCtD
Cyclophosphamide—Thrombocytopenia—Etoposide—muscle cancer	0.00026	0.00062	CcSEcCtD
Cyclophosphamide—Tachycardia—Etoposide—muscle cancer	0.000259	0.000618	CcSEcCtD
Cyclophosphamide—Body temperature increased—Vincristine—muscle cancer	0.000259	0.000618	CcSEcCtD
Cyclophosphamide—Hyperhidrosis—Etoposide—muscle cancer	0.000257	0.000612	CcSEcCtD
Cyclophosphamide—Anorexia—Etoposide—muscle cancer	0.000253	0.000604	CcSEcCtD
Cyclophosphamide—Toxic epidermal necrolysis—Doxorubicin—muscle cancer	0.000252	0.000602	CcSEcCtD
Cyclophosphamide—Diarrhoea—Dactinomycin—muscle cancer	0.000251	0.000599	CcSEcCtD
Cyclophosphamide—Pneumonia—Methotrexate—muscle cancer	0.000251	0.000598	CcSEcCtD
Cyclophosphamide—Nasopharyngitis—Doxorubicin—muscle cancer	0.000251	0.000597	CcSEcCtD
Cyclophosphamide—Hypotension—Etoposide—muscle cancer	0.000248	0.000592	CcSEcCtD
Cyclophosphamide—Stevens-Johnson syndrome—Methotrexate—muscle cancer	0.000247	0.00059	CcSEcCtD
Cyclophosphamide—Renal failure—Methotrexate—muscle cancer	0.000245	0.000585	CcSEcCtD
Cyclophosphamide—Stomatitis—Methotrexate—muscle cancer	0.000243	0.00058	CcSEcCtD
Cyclophosphamide—Conjunctivitis—Methotrexate—muscle cancer	0.000242	0.000578	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Vincristine—muscle cancer	0.000242	0.000576	CcSEcCtD
Cyclophosphamide—Sweating—Methotrexate—muscle cancer	0.000239	0.00057	CcSEcCtD
Cyclophosphamide—Paraesthesia—Etoposide—muscle cancer	0.000238	0.000569	CcSEcCtD
Cyclophosphamide—Haematuria—Methotrexate—muscle cancer	0.000238	0.000567	CcSEcCtD
Cyclophosphamide—Dyspnoea—Etoposide—muscle cancer	0.000237	0.000564	CcSEcCtD
Cyclophosphamide—Asthenia—Vincristine—muscle cancer	0.000235	0.000561	CcSEcCtD
Cyclophosphamide—Vomiting—Dactinomycin—muscle cancer	0.000233	0.000556	CcSEcCtD
Cyclophosphamide—Agranulocytosis—Methotrexate—muscle cancer	0.000233	0.000555	CcSEcCtD
Cyclophosphamide—Rash—Dactinomycin—muscle cancer	0.000231	0.000552	CcSEcCtD
Cyclophosphamide—Decreased appetite—Etoposide—muscle cancer	0.000231	0.00055	CcSEcCtD
Cyclophosphamide—Pancytopenia—Doxorubicin—muscle cancer	0.00023	0.000548	CcSEcCtD
Cyclophosphamide—Fatigue—Etoposide—muscle cancer	0.000229	0.000546	CcSEcCtD
Cyclophosphamide—Pain—Etoposide—muscle cancer	0.000227	0.000541	CcSEcCtD
Cyclophosphamide—Constipation—Etoposide—muscle cancer	0.000227	0.000541	CcSEcCtD
Cyclophosphamide—Haemoglobin—Methotrexate—muscle cancer	0.000225	0.000537	CcSEcCtD
Cyclophosphamide—Diarrhoea—Vincristine—muscle cancer	0.000224	0.000535	CcSEcCtD
Cyclophosphamide—Haemorrhage—Methotrexate—muscle cancer	0.000224	0.000534	CcSEcCtD
Cyclophosphamide—Hepatitis—Methotrexate—muscle cancer	0.000224	0.000534	CcSEcCtD
Cyclophosphamide—Weight increased—Doxorubicin—muscle cancer	0.00022	0.000526	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Etoposide—muscle cancer	0.000219	0.000522	CcSEcCtD
Cyclophosphamide—Hyperglycaemia—Doxorubicin—muscle cancer	0.000219	0.000521	CcSEcCtD
Cyclophosphamide—Nausea—Dactinomycin—muscle cancer	0.000218	0.00052	CcSEcCtD
Cyclophosphamide—Pneumonia—Doxorubicin—muscle cancer	0.000217	0.000518	CcSEcCtD
Cyclophosphamide—Dizziness—Vincristine—muscle cancer	0.000217	0.000517	CcSEcCtD
Cyclophosphamide—Visual impairment—Methotrexate—muscle cancer	0.000216	0.000514	CcSEcCtD
Cyclophosphamide—Stevens-Johnson syndrome—Doxorubicin—muscle cancer	0.000214	0.00051	CcSEcCtD
Cyclophosphamide—Renal failure—Doxorubicin—muscle cancer	0.000212	0.000506	CcSEcCtD
Cyclophosphamide—Erythema multiforme—Methotrexate—muscle cancer	0.000212	0.000505	CcSEcCtD
Cyclophosphamide—Neuropathy peripheral—Doxorubicin—muscle cancer	0.000212	0.000505	CcSEcCtD
Cyclophosphamide—Urticaria—Etoposide—muscle cancer	0.000211	0.000503	CcSEcCtD
Cyclophosphamide—Stomatitis—Doxorubicin—muscle cancer	0.000211	0.000502	CcSEcCtD
Cyclophosphamide—Jaundice—Doxorubicin—muscle cancer	0.000211	0.000502	CcSEcCtD
Cyclophosphamide—Body temperature increased—Etoposide—muscle cancer	0.00021	0.000501	CcSEcCtD
Cyclophosphamide—Conjunctivitis—Doxorubicin—muscle cancer	0.00021	0.0005	CcSEcCtD
Cyclophosphamide—Tinnitus—Methotrexate—muscle cancer	0.000209	0.000498	CcSEcCtD
Cyclophosphamide—Vomiting—Vincristine—muscle cancer	0.000208	0.000497	CcSEcCtD
Cyclophosphamide—Sweating—Doxorubicin—muscle cancer	0.000207	0.000494	CcSEcCtD
Cyclophosphamide—Rash—Vincristine—muscle cancer	0.000207	0.000493	CcSEcCtD
Cyclophosphamide—Dermatitis—Vincristine—muscle cancer	0.000207	0.000492	CcSEcCtD
Cyclophosphamide—Haematuria—Doxorubicin—muscle cancer	0.000206	0.000491	CcSEcCtD
Cyclophosphamide—Headache—Vincristine—muscle cancer	0.000205	0.00049	CcSEcCtD
Cyclophosphamide—Agranulocytosis—Doxorubicin—muscle cancer	0.000202	0.00048	CcSEcCtD
Cyclophosphamide—Chills—Methotrexate—muscle cancer	0.000201	0.000479	CcSEcCtD
Cyclophosphamide—Alopecia—Methotrexate—muscle cancer	0.000198	0.000472	CcSEcCtD
Cyclophosphamide—Bradycardia—Doxorubicin—muscle cancer	0.000197	0.000471	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Etoposide—muscle cancer	0.000196	0.000466	CcSEcCtD
Cyclophosphamide—Erythema—Methotrexate—muscle cancer	0.000195	0.000465	CcSEcCtD
Cyclophosphamide—Haemoglobin—Doxorubicin—muscle cancer	0.000195	0.000465	CcSEcCtD
Cyclophosphamide—Nausea—Vincristine—muscle cancer	0.000195	0.000464	CcSEcCtD
Cyclophosphamide—Rhinitis—Doxorubicin—muscle cancer	0.000194	0.000463	CcSEcCtD
Cyclophosphamide—Haemorrhage—Doxorubicin—muscle cancer	0.000194	0.000462	CcSEcCtD
Cyclophosphamide—Hepatitis—Doxorubicin—muscle cancer	0.000194	0.000462	CcSEcCtD
Cyclophosphamide—Hypoaesthesia—Doxorubicin—muscle cancer	0.000193	0.00046	CcSEcCtD
Cyclophosphamide—Dysgeusia—Methotrexate—muscle cancer	0.000191	0.000455	CcSEcCtD
Cyclophosphamide—Asthenia—Etoposide—muscle cancer	0.000191	0.000454	CcSEcCtD
Cyclophosphamide—Pruritus—Etoposide—muscle cancer	0.000188	0.000448	CcSEcCtD
Cyclophosphamide—Visual impairment—Doxorubicin—muscle cancer	0.000187	0.000445	CcSEcCtD
Cyclophosphamide—Vision blurred—Methotrexate—muscle cancer	0.000184	0.000438	CcSEcCtD
Cyclophosphamide—Erythema multiforme—Doxorubicin—muscle cancer	0.000183	0.000437	CcSEcCtD
Cyclophosphamide—Diarrhoea—Etoposide—muscle cancer	0.000182	0.000433	CcSEcCtD
Cyclophosphamide—Ill-defined disorder—Methotrexate—muscle cancer	0.000181	0.000431	CcSEcCtD
Cyclophosphamide—Tinnitus—Doxorubicin—muscle cancer	0.000181	0.000431	CcSEcCtD
Cyclophosphamide—Anaemia—Methotrexate—muscle cancer	0.00018	0.000429	CcSEcCtD
Cyclophosphamide—Flushing—Doxorubicin—muscle cancer	0.00018	0.000429	CcSEcCtD
Cyclophosphamide—Malaise—Methotrexate—muscle cancer	0.000176	0.000419	CcSEcCtD
Cyclophosphamide—Dizziness—Etoposide—muscle cancer	0.000176	0.000419	CcSEcCtD
Cyclophosphamide—Leukopenia—Methotrexate—muscle cancer	0.000174	0.000416	CcSEcCtD
Cyclophosphamide—Chills—Doxorubicin—muscle cancer	0.000174	0.000415	CcSEcCtD
Cyclophosphamide—Arrhythmia—Doxorubicin—muscle cancer	0.000173	0.000413	CcSEcCtD
Cyclophosphamide—Alopecia—Doxorubicin—muscle cancer	0.000171	0.000408	CcSEcCtD
Cyclophosphamide—Cough—Methotrexate—muscle cancer	0.00017	0.000405	CcSEcCtD
Cyclophosphamide—Convulsion—Methotrexate—muscle cancer	0.000169	0.000403	CcSEcCtD
Cyclophosphamide—Vomiting—Etoposide—muscle cancer	0.000169	0.000403	CcSEcCtD
Cyclophosphamide—Erythema—Doxorubicin—muscle cancer	0.000169	0.000402	CcSEcCtD
Cyclophosphamide—Rash—Etoposide—muscle cancer	0.000167	0.000399	CcSEcCtD
Cyclophosphamide—Dermatitis—Etoposide—muscle cancer	0.000167	0.000399	CcSEcCtD
Cyclophosphamide—Headache—Etoposide—muscle cancer	0.000166	0.000397	CcSEcCtD
Cyclophosphamide—Arthralgia—Methotrexate—muscle cancer	0.000166	0.000396	CcSEcCtD
Cyclophosphamide—Chest pain—Methotrexate—muscle cancer	0.000166	0.000396	CcSEcCtD
Cyclophosphamide—Myalgia—Methotrexate—muscle cancer	0.000166	0.000396	CcSEcCtD
Cyclophosphamide—Dysgeusia—Doxorubicin—muscle cancer	0.000165	0.000394	CcSEcCtD
Cyclophosphamide—Discomfort—Methotrexate—muscle cancer	0.000164	0.000391	CcSEcCtD
Cyclophosphamide—Muscle spasms—Doxorubicin—muscle cancer	0.000162	0.000387	CcSEcCtD
Cyclophosphamide—Confusional state—Methotrexate—muscle cancer	0.00016	0.000382	CcSEcCtD
Cyclophosphamide—Anaphylactic shock—Methotrexate—muscle cancer	0.000159	0.000379	CcSEcCtD
Cyclophosphamide—Vision blurred—Doxorubicin—muscle cancer	0.000159	0.000379	CcSEcCtD
Cyclophosphamide—Infection—Methotrexate—muscle cancer	0.000158	0.000377	CcSEcCtD
Cyclophosphamide—Nausea—Etoposide—muscle cancer	0.000158	0.000376	CcSEcCtD
Cyclophosphamide—Ill-defined disorder—Doxorubicin—muscle cancer	0.000157	0.000373	CcSEcCtD
Cyclophosphamide—Anaemia—Doxorubicin—muscle cancer	0.000156	0.000372	CcSEcCtD
Cyclophosphamide—Thrombocytopenia—Methotrexate—muscle cancer	0.000156	0.000371	CcSEcCtD
Cyclophosphamide—Agitation—Doxorubicin—muscle cancer	0.000155	0.00037	CcSEcCtD
Cyclophosphamide—Hyperhidrosis—Methotrexate—muscle cancer	0.000154	0.000367	CcSEcCtD
Cyclophosphamide—Malaise—Doxorubicin—muscle cancer	0.000152	0.000363	CcSEcCtD
Cyclophosphamide—Anorexia—Methotrexate—muscle cancer	0.000152	0.000361	CcSEcCtD
Cyclophosphamide—Leukopenia—Doxorubicin—muscle cancer	0.000151	0.00036	CcSEcCtD
Cyclophosphamide—Palpitations—Doxorubicin—muscle cancer	0.000149	0.000356	CcSEcCtD
Cyclophosphamide—Hypotension—Methotrexate—muscle cancer	0.000149	0.000354	CcSEcCtD
Cyclophosphamide—Cough—Doxorubicin—muscle cancer	0.000147	0.000351	CcSEcCtD
Cyclophosphamide—Convulsion—Doxorubicin—muscle cancer	0.000146	0.000349	CcSEcCtD
Cyclophosphamide—Hypertension—Doxorubicin—muscle cancer	0.000146	0.000347	CcSEcCtD
Cyclophosphamide—Musculoskeletal discomfort—Methotrexate—muscle cancer	0.000145	0.000346	CcSEcCtD
Cyclophosphamide—Arthralgia—Doxorubicin—muscle cancer	0.000144	0.000343	CcSEcCtD
Cyclophosphamide—Chest pain—Doxorubicin—muscle cancer	0.000144	0.000343	CcSEcCtD
Cyclophosphamide—Myalgia—Doxorubicin—muscle cancer	0.000144	0.000343	CcSEcCtD
Cyclophosphamide—Paraesthesia—Methotrexate—muscle cancer	0.000143	0.000341	CcSEcCtD
Cyclophosphamide—Discomfort—Doxorubicin—muscle cancer	0.000142	0.000338	CcSEcCtD
Cyclophosphamide—Dyspnoea—Methotrexate—muscle cancer	0.000142	0.000338	CcSEcCtD
Cyclophosphamide—Confusional state—Doxorubicin—muscle cancer	0.000139	0.000331	CcSEcCtD
Cyclophosphamide—Decreased appetite—Methotrexate—muscle cancer	0.000138	0.00033	CcSEcCtD
Cyclophosphamide—Anaphylactic shock—Doxorubicin—muscle cancer	0.000138	0.000328	CcSEcCtD
Cyclophosphamide—Oedema—Doxorubicin—muscle cancer	0.000138	0.000328	CcSEcCtD
Cyclophosphamide—Fatigue—Methotrexate—muscle cancer	0.000137	0.000327	CcSEcCtD
Cyclophosphamide—Infection—Doxorubicin—muscle cancer	0.000137	0.000326	CcSEcCtD
Cyclophosphamide—Pain—Methotrexate—muscle cancer	0.000136	0.000324	CcSEcCtD
Cyclophosphamide—Shock—Doxorubicin—muscle cancer	0.000136	0.000323	CcSEcCtD
Cyclophosphamide—Thrombocytopenia—Doxorubicin—muscle cancer	0.000135	0.000322	CcSEcCtD
Cyclophosphamide—Tachycardia—Doxorubicin—muscle cancer	0.000134	0.00032	CcSEcCtD
Cyclophosphamide—Hyperhidrosis—Doxorubicin—muscle cancer	0.000133	0.000317	CcSEcCtD
Cyclophosphamide—Anorexia—Doxorubicin—muscle cancer	0.000131	0.000313	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Methotrexate—muscle cancer	0.000131	0.000313	CcSEcCtD
Cyclophosphamide—Hypotension—Doxorubicin—muscle cancer	0.000129	0.000307	CcSEcCtD
Cyclophosphamide—Urticaria—Methotrexate—muscle cancer	0.000126	0.000301	CcSEcCtD
Cyclophosphamide—Body temperature increased—Methotrexate—muscle cancer	0.000126	0.0003	CcSEcCtD
Cyclophosphamide—Musculoskeletal discomfort—Doxorubicin—muscle cancer	0.000126	0.000299	CcSEcCtD
Cyclophosphamide—Paraesthesia—Doxorubicin—muscle cancer	0.000124	0.000295	CcSEcCtD
Cyclophosphamide—Dyspnoea—Doxorubicin—muscle cancer	0.000123	0.000293	CcSEcCtD
Cyclophosphamide—Decreased appetite—Doxorubicin—muscle cancer	0.00012	0.000285	CcSEcCtD
Cyclophosphamide—Fatigue—Doxorubicin—muscle cancer	0.000119	0.000283	CcSEcCtD
Cyclophosphamide—Pain—Doxorubicin—muscle cancer	0.000118	0.000281	CcSEcCtD
Cyclophosphamide—Constipation—Doxorubicin—muscle cancer	0.000118	0.000281	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Methotrexate—muscle cancer	0.000117	0.000279	CcSEcCtD
Cyclophosphamide—Asthenia—Methotrexate—muscle cancer	0.000114	0.000272	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Doxorubicin—muscle cancer	0.000114	0.000271	CcSEcCtD
Cyclophosphamide—Pruritus—Methotrexate—muscle cancer	0.000113	0.000268	CcSEcCtD
Cyclophosphamide—Urticaria—Doxorubicin—muscle cancer	0.000109	0.000261	CcSEcCtD
Cyclophosphamide—Body temperature increased—Doxorubicin—muscle cancer	0.000109	0.00026	CcSEcCtD
Cyclophosphamide—Diarrhoea—Methotrexate—muscle cancer	0.000109	0.000259	CcSEcCtD
Cyclophosphamide—Dizziness—Methotrexate—muscle cancer	0.000105	0.000251	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Doxorubicin—muscle cancer	0.000101	0.000242	CcSEcCtD
Cyclophosphamide—Vomiting—Methotrexate—muscle cancer	0.000101	0.000241	CcSEcCtD
Cyclophosphamide—Rash—Methotrexate—muscle cancer	0.0001	0.000239	CcSEcCtD
Cyclophosphamide—Dermatitis—Methotrexate—muscle cancer	0.0001	0.000239	CcSEcCtD
Cyclophosphamide—Headache—Methotrexate—muscle cancer	9.97e-05	0.000238	CcSEcCtD
Cyclophosphamide—Asthenia—Doxorubicin—muscle cancer	9.88e-05	0.000236	CcSEcCtD
Cyclophosphamide—Pruritus—Doxorubicin—muscle cancer	9.75e-05	0.000232	CcSEcCtD
Cyclophosphamide—Nausea—Methotrexate—muscle cancer	9.45e-05	0.000225	CcSEcCtD
Cyclophosphamide—Diarrhoea—Doxorubicin—muscle cancer	9.43e-05	0.000225	CcSEcCtD
Cyclophosphamide—Dizziness—Doxorubicin—muscle cancer	9.11e-05	0.000217	CcSEcCtD
Cyclophosphamide—Vomiting—Doxorubicin—muscle cancer	8.76e-05	0.000209	CcSEcCtD
Cyclophosphamide—Rash—Doxorubicin—muscle cancer	8.69e-05	0.000207	CcSEcCtD
Cyclophosphamide—Dermatitis—Doxorubicin—muscle cancer	8.68e-05	0.000207	CcSEcCtD
Cyclophosphamide—Headache—Doxorubicin—muscle cancer	8.63e-05	0.000206	CcSEcCtD
Cyclophosphamide—Nausea—Doxorubicin—muscle cancer	8.18e-05	0.000195	CcSEcCtD
